株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

植物性医薬品・植物由来医薬品:世界市場

Botanical and Plant-Derived Drugs: Global Markets

発行 BCC Research 商品コード 82886
出版日 ページ情報 英文 175 pages
即納可能
価格
本日の銀行送金レート: 1USD=113.80円で換算しております。
Back to Top
植物性医薬品・植物由来医薬品:世界市場 Botanical and Plant-Derived Drugs: Global Markets
出版日: 2017年11月27日 ページ情報: 英文 175 pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界における植物性医薬品・植物由来医薬品の市場規模は、2017年から2022年にかけて6.1%のCAGR (年間複合成長率) で拡大し、2017年の294億米ドルから2022年までに396億米ドルへ成長すると予測されています。

当レポートでは、世界の植物性医薬品・植物由来医薬品市場について調査し、植物性医薬品産業の概要、世界市場の動向分析とCAGR予測、処方薬、産業構造・競合状況・市場成長促進因子の分析、治療分野・地域別の売上分析を含めた市場規模・区分についての議論、植物性医薬品・植物由来医薬品産業の将来展望などについてまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場・技術背景

  • 植物由来医薬品の略歴
  • 将来の機会
  • 始動
  • 主な促進因子
  • 主な課題
  • 米国政府の投資
  • 業界投資動向
  • ケーススタディー:NUTRITION SCIENCE PARTNERS LTD. (NESTLE HEALTH)
  • 植物性医薬品の定義
  • 規制プロセスの理解
  • 新薬臨床試験開始届
    • 臨床試験
    • 新薬の申請
  • 米国で最初・2番目に認可された植物性医薬品
  • 植物性医薬品候補のパイプライン
  • パイプラインの成長
  • 全体的な医薬品情勢
  • 植物性医薬品の主要分類
  • 知的財産権
  • 生産
  • 新たな生産のタイプ:植物性医薬品
  • 医薬品の開発と製造

第4章 市場区分:技術タイプ別

  • 植物由来医薬品の販売:技術別
  • 植物由来医薬品:治療分野別
  • 植物由来医薬品の規模:治療分野別
  • パイプラインの展望:臨床開発における植物性医薬品の構成

第5章 新たな発展と市場機会

  • ホルモン療法と代謝
  • 感染症用途
  • 疼痛および中枢神経系疾患用途
  • 心血管および代謝性疾患用途
  • 呼吸器系、炎症性、自己免疫疾患用途
  • 皮膚病用途
  • 胃腸系用途
  • 癌用途
  • 臨床開発における植物性医薬品

第6章 企業プロファイル

第7章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO022H

Report Highlights

The global market for botanical and plant-derived drugs will grow from $29.4 billion in 2017 to around $39.6 billion by 2022 with a compound annual growth rate (CAGR) of 6.1% for the period of 2017-2022.

Report Includes:

  • 27 tables
  • An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address specific medical conditions or symptoms)
  • Examination of the industry structure, competition, and market drivers
  • Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry

Report Scope

This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.

For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.

The study's main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.

The study also does not cover the following:

  • Underground or illicit drugs.
  • Home remedies.
  • Tribal medicines.
  • Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
  • Nonmedicinal plant substances, such as laxative cellulose and pectin fiber.
  • Intravenously delivered nutrients of plant origin, such as dextrose.
  • Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
  • Plant substances serving in cosmetics, toiletries and personal care products.
  • Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.
  • Marine life.

The format of the study is organized around the following topics:

  • Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
  • Industry structure.
  • Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
  • Market drivers.
  • Market projections through 2022.
  • Competition.
  • Observations and conclusions regarding the future of the botanical and plant-derived drug industry.

Analyst Credentials

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • Trends and Drivers for Botanical Drug Development

Chapter 3: Market and Technology Background

  • Brief History of Plant-Derived Medicines
  • Opportunity Lies Beyond What Is Known
  • Getting Started
  • Key Drivers
  • Key Challenges
  • U.S. Government Investment
  • Industry Investment
  • Nutrition Science Partners Ltd. (Nestlé Health): A Case Study
  • Botanical Drugs Defined
  • Understanding the Regulatory Process
  • Investigational New Drug Applications
    • Clinical Trials
    • New Drug Application
  • The First and Second U.S. Approved Botanical Drug
    • Veregen (Chinese Green Tea Catechins)
    • Mytesi, Formerly Fulyzaq (Crofelemer)
  • Botanical Candidates in the Pipeline
    • Samital
    • Danshen Dripping Pill (Cardiotonic Pill)
    • EISO (East Indian Sandalwood Oil)
    • Microbio and WH-1, MB-6 and OB318
  • A Growing Pipeline
  • Overall Pharma Landscape
  • Major Classes of Plant Drugs
    • Terpenes and Steroids
    • Alkaloids and Glycosides
    • Phenols
    • Proanthocyanidins
    • The Emergence of Cannabinoids
  • Intellectual Property
  • Production
  • A New Type of Production: Plant-Made Drugs
    • Moving Production Forward
    • Supply and Legal Issues
  • Drug Development and Manufacture

Chapter 4: Market Breakdown by Technology Type

  • Sales of Plant-derived Drugs by Region
  • Plant-derived Drugs by Therapeutic Area
  • Value of Plant-derived Drugs by Therapeutic Area
  • A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development

Chapter 5: New Developments and Market Opportunities

  • Hormone Therapy and Metabolism Applications
  • Infectious Disease Applications
  • Pain and Central Nervous System Disease Applications
  • Cardiovascular and Metabolic Applications
  • Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
  • Dermatology Applications
  • Gastrointestinal Applications
  • Oncology Applications
  • Botanical Drugs in Clinical Development
    • Promising Candidates for Botanical Drugs

Chapter 6: Company Profiles

Chapter 7: Appendix

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Botanical and Plant-derived Drugs*, by Type, Through 2022 ($ Millions)
    • Table 1: Key Events Related to Botanical Medicine
    • Table 2: Notable Plant-derived Drugs
    • Table 3: Number of Botanicals Pre-INDS and INDs Submitted to the FDA, by Type, Through 2013 (Units)
    • Table 4: SWOT Analysis of Botanical Drug Development
    • Table 5: Key Investments in Botanical and Other Plant-derived Drugs
    • Table 6: Distinctions Among Products That Use Plants Medicinally
    • Table 7: Botanical Composition of Menerba (MF 101)*
    • Table 8: Top Pharma Companies, by Revenue, 2016 ($ Billions)
    • Table 9: Major Upcoming U.S. Patent Expiries, 2014-2022
    • Table 10: Major Producers of Raw Materials for Plant-Based Medicine
    • Table 11: Key Companies with Natural Product Libraries
    • Table 12: Number of FDA-Approved Botanical Drugs, Through 2022
    • Table 13: Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, Through 2022 ($ Millions)
    • Table 14: Plant-derived Hormone Therapy and Metabolism Drugs in Late-Stage Development
    • Table 15: Plant-derived Infectious Disease Drugs in Late-Stage Development
    • Table 16: Brain Disorders That are Refractory to Small Molecule Drugs
    • Table 17: Plant-derived Pain and CNS Drugs in Late-Stage Development
    • Table 18: Plant-derived Cardiovascular and Metabolic Drugs in Late-Stage Development
    • Table 19: Plant-Derived Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Drugs in Late-Stage Development
    • Table 20: Plant-derived Dermatology/Wound Care Drugs in Late-Stage Development
    • Table 21: Plant-derived Gastrointestinal Drugs in Late-Stage Development
    • Table 22: Estimated U.S. New Cancer Cases, by Gender, 2016
    • Table 23: Plant-derived Oncology Drugs in Late-Stage Development
    • Table 24: Botanical Drugs in Clinical Development with Possible FDA-Approved Commercialization, Through 2022
    • Table 25: Promising Compounds Being Studied for Medicinal/Therapeutic Potential
    • Table 26: Plant-derived Drugs: Their Origin and Actions
    • Table 27: Useful Resources for the Botanical Industry

List of Figures

  • Summary Figure: Global Market for Botanical and Plant-derived Drugs*, by Type, 2016-2022 ($ Millions)
    • Figure 1: Top Therapeutic Areas of FDA Drug Approvals, 2016 (Number, Total = 22)
    • Figure 2: Composition of FDA-Approved Botanical Indications, by Therapeutic Area, 2017 and 2022 (No./%)
    • Figure 3: Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, 2017 and 2022 ($ Millions)
    • Figure 4: Therapeutic Areas Targeted for Botanical Drugs in Phase 2 or Later, 2017* (%)
Back to Top